Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company specializing in hypertension treatments, will release its Q2 2025 financial results on Tuesday, August 12, 2025, after market close. The company will host a conference call at 4:30 p.m. ET the same day.
The company, which focuses on developing medicines for hypertension, hypertensive nephropathy, and obstructive sleep apnea (OSA), will make the earnings call accessible via phone and webcast. Investors can join using domestic (1-877-704-4453) or international (1-201-389-0920) dial-in numbers with conference ID 13754684.
Mineralys Therapeutics (NASDAQ: MLYS), un'azienda biofarmaceutica in fase clinica specializzata in trattamenti per l'ipertensione, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 il martedì 12 agosto 2025, dopo la chiusura del mercato. La società terrà una conference call alle 16:30 ET dello stesso giorno.
L'azienda, che si concentra sullo sviluppo di farmaci per l'ipertensione, la nefropatia ipertensiva e l'apnea ostruttiva del sonno (OSA), renderà la chiamata sugli utili accessibile tramite telefono e webcast. Gli investitori potranno partecipare utilizzando i numeri di telefono nazionali (1-877-704-4453) o internazionali (1-201-389-0920) con ID conferenza 13754684.
Mineralys Therapeutics (NASDAQ: MLYS), una compañía biofarmacéutica en etapa clínica especializada en tratamientos para la hipertensión, publicará sus resultados financieros del segundo trimestre de 2025 el martes 12 de agosto de 2025, después del cierre del mercado. La empresa realizará una llamada conferencia a las 4:30 p.m. ET ese mismo día.
La compañía, que se enfoca en desarrollar medicamentos para la hipertensión, nefropatía hipertensiva y apnea obstructiva del sueño (OSA), hará que la llamada de resultados esté disponible por teléfono y webcast. Los inversores pueden unirse usando los números nacionales (1-877-704-4453) o internacionales (1-201-389-0920) con el ID de conferencia 13754684.
Mineralys Therapeutics (NASDAQ: MLYS)는 고혈압 치료에 특화된 임상 단계의 바이오제약 회사로서, 2025년 2분기 재무 결과를 2025년 8월 12일 화요일 장 마감 후 발표할 예정입니다. 같은 날 오후 4시 30분(동부시간)에 컨퍼런스 콜을 진행합니다.
고혈압, 고혈압성 신병증, 폐쇄성 수면 무호흡증(OSA) 치료제 개발에 집중하는 이 회사는 실적 발표 콜을 전화 및 웹캐스트를 통해 제공할 예정입니다. 투자자들은 국내 전화번호(1-877-704-4453) 또는 국제 전화번호(1-201-389-0920)를 통해 회의 ID 13754684로 참여할 수 있습니다.
Mineralys Therapeutics (NASDAQ : MLYS), une société biopharmaceutique en phase clinique spécialisée dans les traitements de l'hypertension, publiera ses résultats financiers du deuxième trimestre 2025 le mardi 12 août 2025, après la clôture des marchés. La société tiendra une conférence téléphonique à 16h30 ET le même jour.
La société, qui se concentre sur le développement de médicaments pour l'hypertension, la néphropathie hypertensive et l'apnée obstructive du sommeil (AOS), rendra l'appel aux résultats accessible par téléphone et webdiffusion. Les investisseurs peuvent se joindre via les numéros d'appel nationaux (1-877-704-4453) ou internationaux (1-201-389-0920) avec l'ID de conférence 13754684.
Mineralys Therapeutics (NASDAQ: MLYS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Bluthochdruckbehandlungen spezialisiert hat, wird seine Finanzergebnisse für das zweite Quartal 2025 am Dienstag, den 12. August 2025, nach Börsenschluss veröffentlichen. Am selben Tag findet um 16:30 Uhr ET eine Telefonkonferenz statt.
Das Unternehmen, das sich auf die Entwicklung von Medikamenten für Bluthochdruck, hypertensive Nephropathie und obstruktive Schlafapnoe (OSA) konzentriert, wird die Gewinnkonferenz per Telefon und Webcast zugänglich machen. Investoren können über nationale (1-877-704-4453) oder internationale (1-201-389-0920) Einwahlnummern mit der Konferenz-ID 13754684 teilnehmen.
- None.
- None.
RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2025, after the financial markets close on Tuesday, August 12, 2025.
| Tuesday, August 12th @ 4:30 p.m. ET | |
| Domestic: | 1-877-704-4453 |
| International: | 1-201-389-0920 |
| Conference ID: | 13754684 |
| Webcast: | Webcast Link |
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
Contact:
Investor Relations investorrelations@mineralystx.com
Media Relations
Melyssa Weible
Elixir Health Public Relations
Phone:1-201-723-5805
Email: mweible@elixirhealthpr.com
FAQ
When will Mineralys Therapeutics (MLYS) report Q2 2025 earnings?
How can investors access Mineralys Therapeutics Q2 2025 earnings call?
What therapeutic areas does Mineralys Therapeutics (MLYS) focus on?
Where can I find the webcast of Mineralys Therapeutics Q2 2025 earnings call?
